It actually ran to $32 and was completely a pig in a poke at that point based on 4 compassionate use patients and Alkon's hope for a new MOA. No one even knew of its potential in MS. Who knows what happens here but I'm not sure everyone is considering that with Biogen's approval, its an entirely new game in this space. Several other companies coming back into the space who had been sitting it out. Althira finding a potential signal in HGF normalization as well. Folks can invest as they choose of course. People have been saying to sit it out and wait since we were both buying at .80 (3.20 split adjusted) after the merger/spinoff. I don't see how we remain under 20 bucks but that's just me. It's all good.
News 
Market Data 
Discover 
